Back to Journals » Neuropsychiatric Disease and Treatment » Volume 10

Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine

Authors Kishi T, Matsunaga S, Matsuda Y, Iwata N

Received 30 August 2014

Accepted for publication 3 October 2014

Published 10 December 2014 Volume 2014:10 Pages 2339—2351

DOI https://doi.org/10.2147/NDT.S73464

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Wai Kwong Tang

Taro Kishi, Shinji Matsunaga, Yuki Matsuda, Nakao Iwata

Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan

Background: We conducted a meta-analysis of the iminodibenzyl antipsychotics carpipramine, clocapramine, and mosapramine, which are classified as second-generation antipsychotics (SGAs) for schizophrenia treatment.
Methods: We searched data that had been published in PubMed, the Cochrane Library databases, PsycINFO, CiNii, and the Japan Medical Abstracts Society up to August 29, 2014. Randomized controlled trials that compared iminodibenzyl antipsychotics with other antipsychotics in patients with schizophrenia were included. Odds ratios and standardized mean differences were evaluated.
Results: We included four randomized controlled trials on carpipramine (number of patients [n]=290), six on clocapramine (n=1,048), and five on mosapramine (n=986) in the meta-analysis. There were no significant differences in the response rates or in the discontinuation rates either between carpipramine and the other pooled antipsychotics or between clocapramine and the other pooled antipsychotics. On the Positive and Negative Syndrome Scale, mosapramine’s positive subscale scores were superior to those of the other pooled antipsychotics (standard mean of difference =−0.22); however, on that same scale, there were no significant differences in total scores, negative scores, general subscale scores, response rates, or the discontinuation rates between mosapramine and the other pooled antipsychotics. Furthermore, the incidences of extrapyramidal symptoms and of hyperprolactinemia were significantly greater with mosapramine than with the other pooled antipsychotics.
Conclusion: The pharmacological profiles of carpipramine and clocapramine, which are classified as SGAs, were similar to those of first-generation antipsychotics because there were no significant differences in efficacy and safety outcomes. However, mosapramine was associated with a greater risk of extrapyramidal symptoms and hyperprolactinemia than the other SGAs were, although it may be beneficial for the improvement of positive symptoms.

Keywords: carpipramine, clocapramine, mosapramine, schizophrenia, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population

Kishi T, Ikuta T, Matsunaga S, Matsuda Y, Oya K, Iwata N

Neuropsychiatric Disease and Treatment 2017, 13:1281-1302

Published Date: 11 May 2017

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial

Kishi T, Matsuda Y, Matsunaga S, Moriwaki M, Otake Y, Akamatsu K, Okochi T, Hirano S, Funahashi T, Okuda M, Tabuse H, Fujita K, Iwata N

Neuropsychiatric Disease and Treatment 2017, 13:117-125

Published Date: 6 January 2017

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders

Kishi T, Matsuda Y, Matsunaga S, Mukai T, Moriwaki M, Tabuse H, Fujita K, Iwata N

Neuropsychiatric Disease and Treatment 2016, 12:3041-3049

Published Date: 28 November 2016

Memantine for the treatment of frontotemporal dementia: a meta-analysis

Kishi T, Matsunaga S, Iwata N

Neuropsychiatric Disease and Treatment 2015, 11:2883-2885

Published Date: 12 November 2015

Early prediction of blonanserin response in Japanese patients with schizophrenia

Kishi T, Matsuda Y, Fujita K, Iwata N

Neuropsychiatric Disease and Treatment 2014, 10:1861-1866

Published Date: 23 September 2014

Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder

Nagao K, Kishi T, Moriwaki M, Fujita K, Hirano S, Yamanouchi Y, Funahashi T, Iwata N

Neuropsychiatric Disease and Treatment 2013, 9:781-786

Published Date: 5 June 2013

Readers of this article also read:

Parkinson’s disease-associated melanin steal

Hinz M, Stein A, Cole T

Neuropsychiatric Disease and Treatment 2014, 10:2331-2337

Published Date: 10 December 2014

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010